Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome

Hepatology

Volumn 46, Issue 6, 2007, Pages 1863-1871

  Krag, Aleksander ^a,c   Møller, Søren ^a   Henriksen, Jens H ^a   Holstein Rathlou, Niels Henrik ^b   Larsen, Fin Stolze ^a   Bendtsen, Flemming ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; LITHIUM; NORADRENALIN; PLACEBO; RENIN; SODIUM; SPIRONOLACTONE; TERLIPRESSIN;

ABDOMINAL CRAMP; ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LOOSE FECES; MALE; NATRIURESIS; NAUSEA; NORADRENALIN BLOOD LEVEL; OSMOLALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; VASOCONSTRICTION; VOMITING;

ASCITES; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; KIDNEY; KIDNEY DISEASES; LIVER CIRRHOSIS, ALCOHOLIC; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; RECOVERY OF FUNCTION; VASOCONSTRICTOR AGENTS;

EID: 37749053681     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21901     Document Type: Article

References (39)

1. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986;31:468-475.
2. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. HEPATOLOGY 1987;7:122-128.
3. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al., for the International Ascites Club. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996;23:164-176.
4. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
5. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
6. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38(suppl 1):S69-S89.
7. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-158.
8. Moreau R, Durand F, Poynard T, Duhamel C, Jean P, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-930.
9. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type I hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-19.
10. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002;36:941-948.
11. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-156.
12. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
13. Sanyal A, Boyer TD, Garcia-Tsao G, Regenstein F, Rossaro L, Teuber P. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. HEPATOLOGY 2006;44(suppl 1):LB6.
14. Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hyperrensive patients. Liver 2000;20:51-59.
15. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. HEPATOLOGY 2003;38:258-266.
16. Runyon BA. Management of adult patients with ascites due to cirrhosis. HEPATOLOGY 2004;39:841-856.
17. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron 1984;37:217-223.
18. Moller S, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1996;25:316-328.
19. Moller S, Norgaard A, Henriksen JH, Frandsen E, Bendtsen F. Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. HEPATOLOGY 2004;40:811-819.
20. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991;12:118-123.
21. Melander O, Frandsen E, Groop L, Hulthen UL. Plasma ProANP(1-30) reflects salt sensitivity in subjects with heredity for hypertension. Hypertension 2002;39:996-999.
22. Ottesen LH, Aagaard NK, Kiszka-Kanowitz M, Rehling M, Henriksen JH, Pedersen EB, et al. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial. HEPATOLOGY 2001;34:471-477.
23. Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997;26:1229-1234.
24. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-221.
25. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. HEPATOLOGY 1998;28:937-943.
26. Bernardi M, De PR, Trevisani F, Tame MR, Ciancaglini GC, Pesa O, et al. Renal function and effective beta-blockade in cirrhosis with ascites. Relationship with baseline sympathoadrenergic tone. J Hepatol 1989;8:279-286.
27. Stanley AJ, Bouchier IA, Hayes PC. Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients. Gut 1998;42:283-287.
28. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994;203:72-79.
29. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Moller S, Bendtsen F. Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 2004;39:486-492.
30. Thomsen K, Shirley DG. The validity of lithium clearance as an index of sodium and water delivery from the proximal tubules. Nephron 1997;77:125-138.
31. Angeli P, De BE, Dalla PM, Caregaro L, Ceolotto G, Albino G, et al. Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. HEPATOLOGY 1992;15:651-654.
32. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:413-417.
33. Manning PT, Schwartz D, Katsube NC, Holmberg SW, Needleman P. Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985;229:395-397.
34. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982;307:1552-1557.
35. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 1990;70:1067-1116.
36. Coppage WS, Island DP, Cooner AE, Liddle GW. The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis. J Clin Invest 1962;41:1672.
37. Vecsei P, Dusterdieck G, Jahnecke J, Lommer D, Wolff HP. Secretion and turnover of aldosterone in various pathological states. Clin Sci 1969;36:241-256.
38. Yeates KE, Morton AR. Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol 2006;26:348-355.
39. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.